References

  1. Nurmagambetov T. The economic burden of asthma in the United States, 2008-2013. Ann Am Thorac Soc. 2018
  2. Backman H, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016—results from three population surveys. Clin Exp Allergy. 2017
  3. Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy. 2008
  4. American College of Asthma, Allergy and Immunology https://acaai.org/news/facts-statistics/asthma accessed 08-27-2020
  5. Global Initiative for Asthma (GINA). Diagnosis and Management of Difficult-to-treat and Severe Asthma - Global Initiative for Asthma - GINA. https://ginasthma.org/severeasthma2018/. Published 2018. Accessed January 2, 2019.
  6. GINA 2018 Global Strategy for Asthma Management and Prevention. 2018. www.ginasthma.org.
  7. Busse, William et al. Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study. Journal of Allergy and Clinical Immunology, Volume 145, Issue 2, AB21
  8. Matsunaga K, Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int. 2016
  9. Van Veen IH, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J. 2008
  10. Alcázar-Navarrete, et. Al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018
  11. R. Shrimanker, et.al. FeNO and Peripheral Blood Eosinophil Count Prognostic and Predictive Biomarkers in Severe Eosinophilic Asthma
  12. Dweik RA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010.
  13. Understanding Type 2 Inflammation https://www.type2inflammation.com. Accessed June 1, 2020.
  14. Dupixent for Moderate-to-Severe asthma https://www.dupixenthcp.com/asthma. Accessed June 1, 2020.
  15. Wang Z, et al. Comparative Effectiveness Review The Clinical Utility of FeNO in Asthma Management. 2017.
  16. Dweik RA, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011.
  17. NICE. Measuring fractional exhaled nitric oxide concentration in asthma : NIOX MINO , NIOX VERO and NObreath. 2014;(April):1-46.
  18. NICE. Asthma : diagnosis , monitoring and chronic asthma management | Guidance and guidelines Accessed May 15, 2018.
  19. AAAAI/ACAAI Joint Statement of Support of the ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide for Clinical Applications. Accessed August 8, 2019
  20. Halterman JS, Fagnano M, Tajon RS, et al. Effect of the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) Program on Asthma Morbidity. JAMA Pediatr. January 2018
  21. U.S. Department of Health and Human Services. (n.d.). 2020 focused updates to the asthma management guidelines. National Heart Lung and Blood Institute. Retrieved September 29, 2021, from https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates.
  22. Couillard S, Laugerud A, Jabeen M, et al Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide Thorax Published Online First: 06 August 2021. doi: 10.1136/thoraxjnl-2021-217325